Dr Reddy's gets warning from US health regulator
'We lost our place in being first in the epidemic, when it hit India so hard, but we were actually the epicentre of the epidemic from essentially April 2020, for almost an entire year. We had such high cases. We were the country that had the most mixed response.'
'The government had a vaccine from January.' 'The government should have given the vaccine to all population above the age of 45, right from the start.' 'Each state has its own problems, but as far as vaccine coverage in India is concerned, there have been mistakes.'
These vaccines have not yet been approved by the World Health Organization
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
With an increasing number of people from the Indian-American community playing a significant role in US elections, Congressman Raja Krishnamoorthi said there is a realisation among them that "if you don't have a seat at the table, you're on the menu -- that is why they are voting and running for office in large numbers".
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
This may include Rs 1,500 as a screening test for suspect cases and an additional Rs 3,000 for confirmation test, the guidelines said.
Data also show that several other leading domestic pharma companies have recalled their products from the US
As states grapple with a shortage of coronavirus vaccines, the Centre on Thursday said that over two billion doses will be made available in the country in five months between August and December, enough to vaccinate the entire population.
Illustrious international thinkers met at the Milken Institute Global Conference 2021 and many discussions addressed the impact of the COVID-19 pandemic on the world at large.
As the global debate on booster shots gathers momentum, several scientists in New Delhi said the priority must be to ensure that more people are inoculated with at least their first jab.
The first two coaches that rolled out from the Railway Coach Factory in Kapurthala also have fixtures coated with titanium dioxide and the provision for plasma air equipment in AC ducts to sterilise interiors using ionised air. Railway Minister Piyush Goyal also indicated that the new coaches could be the new normal.
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
Soon after Trump revealed to the world that he has been taking the medicine, the White House doctor said the president is in good health.
Maggi noodles was recalled in June because some states had found presence of MSG and excessive lead content in the samples.
Overall, the credit profiles of players will be supported by healthy balance sheets and liquidity. Prudence in capital and development expenditure, efficient working-capital management, and recent equity raising will help sustain credit metrics in FY22.
the Maharashtra Food and Drug Administration on Saturday issued directives to various departments to cancel the licences of gutkha manufacturers, wholesalers and retailers in the state after finding magnesium carbonate in gutkha.
The US market for the drug is pegged at $1 billion. Cipla has been selling the product in the European market. It had won a similar case in the UK against GSK a couple of years ago.
The move follows an FDA inspection of a Ranbaxy facility which identified significant violations of sound manufacturing practices.
Sun Pharma's acquisition of Ranbaxy has once again revived evaluation of the troubled past of the latter, which had changed hands from the promoters merely five years ago.
'Nobody is attacking the company or the vaccine.' 'The concerns are about the process and the lack of transparency.'
Some US doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration.
The move comes after a FDA notice to gutkha manufacturers to mention the contents of their product on the cover.
For Sun Pharma, it is an astute purchase that it hopes will not only boost its position in India but also globally.
These drugs will be entering in their global Phase -3 clinical trials early next year.
The Japanese company alleges the earlier Ranbaxy promoters withheld crucial information when they sold the company in 2008.
After recovering from issues such as defaults on foreign currency convertible bonds and piling debts, pharmaceutical major Wockhardt has been on the slow lane through the last six months, following warnings from global regulators such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency.
The pain relieving balm is made available at more than 1,000 retail stores in 75 different cities in 12 states in India
The tests, according to the report, showed that Pepsi products from its plant in Khalapur in Raigad district contained 0.6 mg of lindane, which is above the permissible limits.
'We built it in the last three years and then one day, they came and they said you have to close it'
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances